Details for Patent: 9,125,909
✉ Email this page to a colleague
Which drugs does patent 9,125,909 protect, and when does it expire?
Patent 9,125,909 protects TRINTELLIX and is included in one NDA.
Protection for TRINTELLIX has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has ninety-two patent family members in thirty-four countries.
Summary for Patent: 9,125,909
| Title: | 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT.sub.3 and 5-HT.sub.1A activity for the treatment of cognitive impairment |
| Abstract: | This disclosure relates to 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine or a pharmaceutically acceptable salt thereof in a crystalline form. |
| Inventor(s): | Bang-Andersen; Benny (Copenhagen S, DK), Faldt; Andre (Vejlebrovej, DK), Mork; Arne (Malov, DK), de Diego; Heidi Lopez (Naerum, DK), Holm; Rene (Jyllinge, DK), Stensbol; Tine Bryan (Vaerlose, DK) |
| Assignee: | H. Lundbeck A/S (Copenhagen-Valby, DK) |
| Application Number: | 14/326,725 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,125,909 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; Dosage form; |
More… ↓ |
Drugs Protected by US Patent 9,125,909
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Takeda Pharms Usa | TRINTELLIX | vortioxetine hydrobromide | TABLET;ORAL | 204447-001 | Sep 30, 2013 | RX | Yes | No | 9,125,909*PED | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| Takeda Pharms Usa | TRINTELLIX | vortioxetine hydrobromide | TABLET;ORAL | 204447-002 | Sep 30, 2013 | RX | Yes | No | 9,125,909*PED | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| Takeda Pharms Usa | TRINTELLIX | vortioxetine hydrobromide | TABLET;ORAL | 204447-003 | Sep 30, 2013 | DISCN | Yes | No | 9,125,909*PED | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| Takeda Pharms Usa | TRINTELLIX | vortioxetine hydrobromide | TABLET;ORAL | 204447-004 | Sep 30, 2013 | RX | Yes | Yes | 9,125,909*PED | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 9,125,909
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| Denmark | 2006 00824 | Jun 16, 2006 |
| Denmark | 2006 01223 | Sep 22, 2006 |
| Denmark | 2006 01384 | Oct 25, 2006 |
| Denmark | 2007 00427 | Mar 20, 2007 |
International Family Members for US Patent 9,125,909
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 061481 | ⤷ Subscribe | |||
| Argentina | 065797 | ⤷ Subscribe | |||
| Austria | E495745 | ⤷ Subscribe | |||
| Austria | E540941 | ⤷ Subscribe | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
